Ronald F. Wolf

Complications nearly double the cost of care after pancreaticoduodenectomy

BACKGROUND Despite considerable data focused on the morbidity of pancreaticoduodenectomy (PD), the financial impact of complications has been infrequently analyzed. This study evaluates the impact of the most common complications associated with PD on the cost of care. Additionally, we identified cost centers that were significantly affected by complications. METHODS A retrospective analysis of a prospective database in a network of community-based teaching hospitals was performed. All patients (n = 145) who underwent PD were included for years 2005 to 2009. Of these, 144 had complete in-hospital cost data. Complications were assessed and classified into major and minor categories according to Dindo et al. Forty-nine cost centers were analyzed for their association with the cost of complications. Univariate and multivariate linear regression analyses were performed. Significance was reported for P < .05. RESULTS The median cost for PD was

Surgeon Volume Versus Morbidity and Cost in Patients Undergoing Pancreaticoduodenectomy in an Academic Community Medical Center

30,937. Patients with major complications had significantly higher median cost compared with those without (

Neoadjuvant radiation therapy and its impact on complications after pancreaticoduodenectomy for pancreatic cancer: analysis of the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP)

56,224 vs

Umbilical Hernia Repair in Patients With Signs of Portal Hypertension: Surgical Outcome and Predictors of Mortality

29,038; P < .001). Independent predictors of increased cost included reoperation; sepsis; pancreatic fistula; bile leak; delayed gastric emptying; and pulmonary, renal, and thromboembolic complications. Cost center analysis showed significant added charges for patients with major complications for blood bank (

Impact of lymph node status in patients with intrahepatic cholangiocarcinoma treated by major hepatectomy: a review of the National Cancer Database

1,018), clinical laboratory (

Argon ion beam hemostasis with albumin after liver resection

3,731), a computed tomography scan (

Evaluation of a minimally invasive image-guided surgery system for hepatic ablation procedures.

4,742), diagnostic imaging (

Surgical management of breast cancer liver metastases

697), intensive care unit (

Light-guided lumpectomy: device and case report

4,986), pharmacy (

Ablative Technologies for Hepatocellular, Cholangiocarcinoma, and Metastatic Colorectal Cancer of the Liver

33,850) and respiratory therapy (